AEterna Zentaris (USA)(NASDAQ:AEZS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $96.00K. Analysts estimated a revenue of $750.00K. Earnings per share were $-0.71. Analysts had estimated an EPS of $-0.82.
AEterna Zentaris (USA) (AEZS) remained unchanged at the close of Wednesday session. Even as the volume increased to 1,14,603 ,the shares failed to make any impression and ended at 0 points or 0.00% at $3.65. The trading session commenced at $3.6 and the stock hit a high of $3.71 and touched $3.58 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $15.7 and the 52-week low is $2.6. The company has a market cap of $36 M and has approximately 99,39,863 outstanding shares.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH based in Frankfurt Germany Zentaris IVF GmbH a direct wholly owned subsidiary of AEZS Germany based in Frankfurt Germany and Aeterna Zentaris Inc. Its drug development efforts are focused on two compounds zoptarelin doxorubicin and Macrilen which are in clinical development and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates) which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.